NEW YORK — Novo Nordisk AS says the Food and Drug Administration rejected its applications for approval of once-per-day insulin drugs to treat diabetes.
The Danish drugmaker says it received a “complete response letter” from the FDA regarding its applications for approval of Tresiba and Ryzodeg, or insulin degludec, on Friday. Such a letter indicates the agency determined the application cannot be approved in its current form.
Tresiba contains long-acting insulin, and Ryzodeg contains both long- and short-acting insulins.
No comments:
Post a Comment